Element Biosciences, Inc.

Element Biosciences, Inc.

Element Biosciences, Inc. is a private biotechnology company founded in 2017 that develops and manufactures genetic analysis tools. Headquartered in San Diego, California, the company is a venture-backed startup focused on the research and diagnostic markets. As a private entity, it does not have a stock ticker. Various sources place its employee count between approximately 300 and 480 people. In January 2024, the company announced it had generated over $25 million in revenue in 2023.

Element Biosciences develops and sells DNA sequencing platforms. Its primary product line is the AVITI™ system, a benchtop DNA sequencer designed to provide high-quality data at a lower cost. The company's technology portfolio also includes the recently announced VITARI™, a high-throughput sequencing system, and the AVITI24™, which integrates sequencing and cyto-profiling for multi-omics analysis. These platforms are used by academic institutions, clinical laboratories, and pharmaceutical companies for applications in areas such as cancer research, clinical research, and agriculture.

As an operating company, Element Biosciences appears in patent litigation as a defendant. The company's patent litigation history in the provided database consists of one case where it is named as a defendant. This defensive posture is typical for technology manufacturers and operating companies that are targets of patent assertions by competitors or other patent holders.

The single tracked case is 10x Genomics, Inc. et al. v. Element Biosciences, Inc., filed on May 8, 2026, in the U.S. District Court for the District of Delaware. 10x Genomics, a competitor in the life sciences technology space, is the plaintiff in this suit.